Regen BioPharma, Inc. (RGBP)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Sep 8, 2026, 3:02 PM EST
Regen BioPharma Balance Sheet
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Cash & Equivalents | 0 | 0.07 | 0 | 0.12 | 0.05 | 0.73 |
Cash & Short-Term Investments | 0 | 0.07 | 0 | 0.12 | 0.05 | 0.73 |
Cash Growth | -86.43% | 9614.39% | -99.41% | 136.38% | -92.96% | - |
Accounts Receivable | 0.29 | 0.2 | 0.09 | - | 0.25 | 0.21 |
Other Receivables | - | - | - | - | - | 0 |
Receivables | 0.29 | 0.2 | 0.09 | - | 0.25 | 0.22 |
Prepaid Expenses | 0 | 0 | 0.05 | 0.01 | 0.03 | 0.05 |
Total Current Assets | 0.29 | 0.27 | 0.14 | 0.13 | 0.34 | 0.99 |
Long-Term Investments | - | - | 0.02 | 0.22 | 0.22 | 0.22 |
Total Assets | 0.29 | 0.27 | 0.16 | 0.35 | 0.56 | 1.21 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Accounts Payable | 0.02 | 0 | 0.03 | 0.03 | 0.03 | 0.09 |
Accrued Expenses | 2.01 | 1.84 | 1.66 | 1.64 | 2 | 2.27 |
Short-Term Debt | 0.17 | 0.19 | 0.29 | 0.1 | 0 | 1.43 |
Current Portion of Long-Term Debt | 0.73 | 1.01 | 0.5 | 0.51 | 1.27 | 2.15 |
Current Unearned Revenue | 1.24 | 1.34 | 1.47 | 1.61 | 1.72 | 1.84 |
Other Current Liabilities | 2 | 2.18 | 1.43 | 1.42 | 3.57 | 6.91 |
Total Current Liabilities | 6.17 | 6.56 | 5.38 | 5.31 | 8.6 | 14.7 |
Long-Term Debt | - | - | - | 0.15 | - | - |
Total Liabilities | 6.17 | 6.56 | 5.38 | 5.46 | 8.6 | 14.7 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Common Stock | 0.11 | 0 | 0 | 0 | 0.5 | 0.44 |
Additional Paid-In Capital | 16.52 | 15.63 | 15.4 | 14.64 | 12.32 | 9.38 |
Retained Earnings | -22.31 | -21.69 | -20.42 | -19.75 | -20.91 | -23.35 |
Comprehensive Income & Other | -0.22 | -0.22 | -0.2 | -0 | - | - |
Total Common Equity | -5.89 | -6.28 | -5.22 | -5.1 | -8.08 | -13.53 |
Shareholders' Equity | -5.88 | -6.28 | -5.22 | -5.1 | -8.04 | -13.49 |
Total Liabilities & Equity | 0.29 | 0.27 | 0.16 | 0.35 | 0.56 | 1.21 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Total Debt | 0.89 | 1.2 | 0.79 | 0.76 | 1.27 | 3.58 |
Net Cash (Debt) | -0.89 | -1.13 | -0.79 | -0.64 | -1.22 | -2.86 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -0.00 | -0.05 | -0.10 | -0.09 | -0.19 | -0.71 |
Filing Date Shares Outstanding | 1,675 | 108.05 | 10.52 | 7.12 | 6.71 | 6.09 |
Total Common Shares Outstanding | 1,130 | 39.37 | 10.52 | 7.01 | 6.71 | 5.8 |
Working Capital | -5.88 | -6.28 | -5.24 | -5.18 | -8.26 | -13.7 |
Book Value Per Share | -0.01 | -0.16 | -0.50 | -0.73 | -1.21 | -2.33 |
Tangible Book Value | -5.89 | -6.28 | -5.22 | -5.1 | -8.08 | -13.53 |
Tangible Book Value Per Share | -0.01 | -0.16 | -0.50 | -0.73 | -1.21 | -2.33 |